CLSP-5282 / Clasp Therapeutics - LARVOL DELTA

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101) (clinicaltrials.gov) - P1 | N=140 | Not yet recruiting | Sponsor: Clasp Therapeutics, Inc.

New P1 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

CLSP-5282, a first-in-class T cell engager targeting KRasG12V mutant peptide presented on HLA-A*03:01 (AACR 2026) - "These preclinical data support clinical evaluation of CLSP-5282 in HLA-A*03:01 positive patients with solid tumors harboring the KRasG12V mutation. CLSP-5282 is expected to be the first TCE in the clinic directed against mutant KRas, providing tumor targeting without the risk of on-target, off-tumor toxicity. Our data demonstrate the potential for CLSP-5282 to be efficacious even in the context of resistance to small molecule KRas inhibitors."

Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS